High Tower Advisors, LLC Affimed N.V. Call Options Transaction History

High Tower Advisors, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 10, 2021	SELL	$5.12 - $8.48 $337 - $559	-66 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$3.16 - $7.03 $123,031 - $273,706	-38,934 Reduced 99.83%	66 $7,000
Q3 2020 Nov 13, 2020	BUY	$3.26 - $4.73 $74,980 - $108,790	23,000 Added 143.75%	39,000 $40,000
Q2 2020 Aug 10, 2020	SELL	$1.58 - $4.63 $74,260 - $217,610	-47,000 Reduced 74.6%	16,000 $40,000
Q1 2020 May 21, 2020	SELL	$1.44 - $3.02 $64,800 - $135,900	-45,000 Reduced 41.67%	63,000 $11,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $63,000 - $85,960	28,000 Added 35.0%	108,000 $39,000
Q3 2019 Nov 12, 2019	BUY	$2.67 - $3.65 $48,060 - $65,700	18,000 Added 29.03%	80,000 $48,000
Q2 2019 Aug 13, 2019	SELL	$2.6 - $4.21 $26,000 - $42,100	-10,000 Reduced 13.89%	62,000 $47,000
Q1 2019 May 15, 2019	BUY	$3.05 - $4.34 $173,850 - $247,380	57,000 Added 380.0%	72,000 $103,000
Q3 2018 Nov 09, 2018	BUY	$1.45 - $6.15 $21,750 - $92,250	15,000 New	15,000 $12,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.